MENU
+Compare
LCTX
Stock ticker: ASE
AS OF
Sep 5, 04:59 PM (EDT)
Price
$1.22
Change
+$0.02 (+1.67%)
Capitalization
278.59M

LCTX Lineage Cell Therapeutics Forecast, Technical & Fundamental Analysis

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases... Show more

LCTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for LCTX with price predictions
Sep 04, 2025

LCTX in downward trend: price expected to drop as it breaks its higher Bollinger Band on August 15, 2025

LCTX broke above its upper Bollinger Band on August 15, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 42 similar instances where the stock broke above the upper band. In of the 42 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for LCTX moved out of overbought territory on August 20, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 65 cases where LCTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for LCTX turned negative on September 04, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LCTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 04, 2025. You may want to consider a long position or call options on LCTX as a result. In of 114 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LCTX advanced for three days, in of 218 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 157 cases where LCTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LCTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.757) is normal, around the industry mean (20.013). P/E Ratio (0.000) is within average values for comparable stocks, (51.928). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.122). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (24.691) is also within normal values, averaging (326.881).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
LCTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

LCTX is expected to report earnings to fall 81.31% to -2 cents per share on November 05

Lineage Cell Therapeutics LCTX Stock Earnings Reports
Q3'25
Est.
$-0.02
Q2'25
Missed
by $0.10
Q1'25
Beat
by $0.01
Q4'24
Beat
by $0.01
Q3'24
Beat
by $0.02
The last earnings report on August 12 showed earnings per share of -12 cents, missing the estimate of -2 cents. With 700.16K shares outstanding, the current market capitalization sits at 278.59M.
A.I. Advisor
published General Information

General Information

a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, and neurological conditions

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2173 Salk Avenue
Phone
+1 442 287-8990
Employees
75
Web
https://www.lineagecell.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CRYBF0.04N/A
+2.19%
Dynamite Blockchain Corp.
BHKLY95.49N/A
N/A
BOC Hong Kong (Holdings) Ltd.
IMDZF133.20N/A
N/A
IMCD NV
CNBP93.00N/A
N/A
Cornerstone Bancorp Inc.
SDRMF4.21N/A
N/A
SITEMINDER LTD

LCTX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, LCTX has been loosely correlated with MDGL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if LCTX jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LCTX
1D Price
Change %
LCTX100%
-2.44%
MDGL - LCTX
43%
Loosely correlated
-0.93%
PYXS - LCTX
36%
Loosely correlated
+9.52%
AXON - LCTX
33%
Loosely correlated
+0.67%
MGNX - LCTX
33%
Poorly correlated
+1.57%
BEAM - LCTX
32%
Poorly correlated
-1.17%
More